finance.yahoo.com
Positivefinance.yahoo.com ·
harvard bioscience inc q1 2026 170824125
TAX_FNCACT_DRIVERSECON_STOCKMARKETUNGP_FORESTS_RIVERS_OCEANSTAX_FNCACT_EMPLOYEE
Topic context
This topic has been covered 356504 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedHarvard Bioscience (life sciences tools) is shifting to higher-margin translational science, with NPI driving margin expansion. The company benefits from pharma/biotech R&D spending. Impact is single-company/supply-chain-specific, not global macro. No scarcity or price shock.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- NPI portfolio grew to over 12% of total revenue
- Sales to pharma/biotech customers increased over 20% YoY
- Adjusted gross margin improved ~300 bps to 59%
- Manufacturing consolidation to save $3M in 2027, $4M annually thereafter
- FY2026 guidance: revenue growth 2-4%, adjusted EBITDA growth 6-10%
Related stories
finance.yahoo.com
ncmi q1 2026 earnings transcript 154748256
finance.yahoo.com
fluent q1 2026 earnings call 212653048
economictimes.indiatimes.com
zydus lifesciences shares jump 6 on buyback buzz co announces 166 mn assertio acquisition
finance.yahoo.com
stocks finish higher solid earnings 203348090
finance.yahoo.com